Your browser doesn't support javascript.
loading
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
Ohama, Hideko; Hiraoka, Atsushi; Tada, Toshifumi; Hirooka, Masashi; Kariyama, Kazuya; Hatanaka, Takeshi; Tani, Joji; Takaguchi, Koichi; Atsukawa, Masanori; Itobayashi, Ei; Nishimura, Takashi; Tsuji, Kunihiko; Tajiri, Kazuto; Ishikawa, Toru; Yasuda, Satoshi; Toyoda, Hidenori; Fukunishi, Shinya; Ogawa, Chikara; Kakizaki, Satoru; Shimada, Noritomo; Naganuma, Atsushi; Kawata, Kazuhito; Kosaka, Hisashi; Kuroda, Hidekatsu; Matono, Tomomitsu; Yata, Yutaka; Ochi, Hironori; Tada, Fujimasa; Nouso, Kazuhiro; Morishita, Asahiro; Itokawa, Norio; Okubo, Tomomi; Arai, Taeang; Tsutsui, Akemi; Nagano, Takuya; Yokohama, Keisuke; Nishikawa, Hiroki; Imai, Michitaka; Koizumi, Yohei; Nakamura, Shinichiro; Iijima, Hiroko; Kaibori, Masaki; Hiasa, Yoichi; Kumada, Takashi.
Affiliation
  • Ohama H; Ehime Prefectural Central Hospital, Gastroenterology Center, Matsuyama, Ehime, Japan.
  • Hiraoka A; Ehime Prefectural Central Hospital, Gastroenterology Center, Matsuyama, Ehime, Japan.
  • Tada T; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Hyogo, Japan.
  • Hirooka M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
  • Kariyama K; Department of Hepatology, Okayama City Hospital, Okayama, Japan.
  • Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Gunma, Japan.
  • Tani J; Department of Gastroenterology and Hepatology, Kagawa University, Takamatsu, Kagawa, Japan.
  • Takaguchi K; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan.
  • Atsukawa M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Itobayashi E; Department of Gastroenterology, Asahi General Hospital, Chiba, Japan.
  • Nishimura T; Department of Gastroenterology and Hepatology, Hyogo Medical University, Kochi, Hyogo, Japan.
  • Tsuji K; Teine Keijinkai Hospital, Center of Gastroenterology, Sapporo, Hokkaido, Japan.
  • Tajiri K; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
  • Ishikawa T; Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
  • Yasuda S; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.
  • Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.
  • Fukunishi S; Department of Gastroenterology and Hepatology, Hyogo Medical University, Kochi, Hyogo, Japan.
  • Ogawa C; Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Kagawa, Japan.
  • Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Gunma, Japan.
  • Shimada N; Division of Gastroenterology and Hepatology, Otakanomori Hospital, Chiba, Japan.
  • Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Gunma, Japan.
  • Kawata K; Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Shizuoka, Japan.
  • Kosaka H; Department of Surgery, Kansai Medical University, Osaka, Japan.
  • Kuroda H; Division of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Iwate, Japan.
  • Matono T; Department of Gastroenterology, Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan.
  • Yata Y; Department of Gastroenterology, Hanwa Memorial Hospital, Osaka, Japan.
  • Ochi H; Japanese Red Cross Matsuyama Hospital, Hepato-biliary Center, Matsuyama, Ehime, Japan.
  • Tada F; Ehime Prefectural Central Hospital, Gastroenterology Center, Matsuyama, Ehime, Japan.
  • Nouso K; Department of Hepatology, Okayama City Hospital, Okayama, Japan.
  • Morishita A; Department of Gastroenterology and Hepatology, Kagawa University, Takamatsu, Kagawa, Japan.
  • Itokawa N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Okubo T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Arai T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Tsutsui A; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan.
  • Nagano T; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan.
  • Yokohama K; Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Nishikawa H; Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Imai M; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
  • Koizumi Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
  • Nakamura S; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Hyogo, Japan.
  • Iijima H; Department of Gastroenterology and Hepatology, Hyogo Medical University, Kochi, Hyogo, Japan.
  • Kaibori M; Department of Surgery, Kansai Medical University, Osaka, Japan.
  • Hiasa Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
  • Kumada T; Department of Nursing, Gifu Kyoritsu University, Gifu, Japan.
Cancer Rep (Hoboken) ; 7(4): e2042, 2024 Apr.
Article de En | MEDLINE | ID: mdl-38577725
ABSTRACT

AIMS:

The aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment.

METHODS:

A total of 719 patients (males 577, median age 74 years) treated with Atez/Bev between September 2020 and January 2023 were enrolled. Factors related to overall survival (OS) were extracted and a prognostic scoring system based on hazard ratio (HR) was created. OS and progression-free survival (PFS) were retrospectively examined, and the prognostic ability of the newly developed system was compared to CRAFITY score using concordance index (c-index) and Akaike information criterion (AIC) results.

RESULTS:

Cox-hazards multivariate analysis showed BCLC classification C/D (HR 1.4; 1 point), AFP ≥100 ng/mL (HR 1.4; 1 point), mALBI 2a (HR 1.7; 1 point), mALBI 2b/3 (HR 2.8; 2 points), and DCP ≥100 mAU/mL (HR 1.6; 1 point) as significant factors. The assigned points were added and used to develop the IMmunotherapy with AFP, BCLC staging, mALBI, and DCP evaluation (IMABALI-De) scoring system. For IMABALI-De scores of 0, 1, 2, 3, 4, and 5, OS was not applicable (NA), NA, 26.11, 18.79, 14.07, and 8.32 months, respectively (p < .001; AIC 2788.67, c-index 0.699), while for CRAFITY scores of 0, 1, and 2, OS was 26.11, 20.29, and 11.32 months, respectively (p < .001; AIC 2864.54, c-index 0.606). PFS periods for those IMABALI-De scores were 21.75, 12.89, 9.18, 8.0, 5.0, and 3.75 months, respectively (p < .001; AIC 5203.32, c-index 0.623) and for the CRAFITY scores were 10.32, 7.68, and 3.57 months, respectively (p < .001; AIC 5246.61, c-index 0.574). As compared with CRAFITY score, IMABALI-De score had better AIC and c-index results for both OS and PFS.

CONCLUSION:

The present results indicated that the proposed IMABALI-De score may be favorable for predicting prognosis of uHCC patients receiving Atez/Bev therapy.
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome hépatocellulaire / Anticorps monoclonaux humanisés / Tumeurs du foie Limites: Aged / Humans / Male Langue: En Journal: Cancer Rep (Hoboken) Année: 2024 Type de document: Article Pays d'affiliation: Japon Pays de publication: États-Unis d'Amérique
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome hépatocellulaire / Anticorps monoclonaux humanisés / Tumeurs du foie Limites: Aged / Humans / Male Langue: En Journal: Cancer Rep (Hoboken) Année: 2024 Type de document: Article Pays d'affiliation: Japon Pays de publication: États-Unis d'Amérique